H. Lee Moffitt Cancer Center and Research Institute: Urinary Bladder Neoplasms trials

The registry lists 11 Urinary Bladder Neoplasms studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 5Phase 2 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology AgentsRecruitingNCT06963346Phase 1
• Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the BladderTerminatedNCT02901548Phase 2Results posted
• Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced CholangiocarcinomaCompletedNCT02631590Phase 2Results posted
• Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder CancerCompletedNCT02300610Phase 1Results posted
• Oral Lenalidomide and Intravesical BCG for Therapy of Bladder CancerCompletedNCT01373294Phase 2Results posted
• Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBCActive, not recruitingNCT05768347Phase 1
• Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2
• Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBCCompletedNCT04610671Phase 1
• Addressing Barriers to Palliative Care Use in Bladder CancerCompletedNCT04598724
• Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer ChemopreventionWithdrawnNCT03517995Phase 2
• R115777 in Treating Patients With Advanced Bladder CancerCompletedNCT00006376Phase 2